• About Us
    • Overview
    • Senior Team
    • Board of Non-Executive Directors
    • Investors & Shareholders
  • Our Technology
  • Pipeline
  • NephroScan®
  • News & Events
    • Press Releases
    • In the News
    • Events
    • Publications
  • Careers
  • Contact
  • Menu Menu

About Us

Ariceum Therapeutics is a private company focused on developing novel targeted radiopharmaceuticals for the treatment of cancer

Our lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours, which currently have few treatment options and a poor prognosis.

Our second more advanced therapeutic product, ATT001 is a novel 123Iodine radiolabeled PARP inhibitor (rPARPi) which will soon enter a Phase 1 clinical study in recurrent glioblastoma patients, an indication of high unmet medical need. Ariceum intends to expand the development of ATT001 into other fast growing PARP expressing tumours.

Through our partnership with UCB Pharma, we will explore new targets to develop first-in-class radiopharmaceuticals to continue expanding our pipeline beyond the two lead assets.

Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen.

Headquartered in Berlin, Ariceum has operations in Germany, Switzerland and Australia, and is active across Europe, North America and Australia.

Milestones

  • October 2021

    Satoreotide bought out from
    IPSEN by VC Syndicate

  • June 2022

    Launch of Ariceum and series A €25 million

  • April 2023

    Series A extension €22.75 million

  • May 2023

    Strategic Research Collaboration with UCB

  • June 2023

    Acquisition of Theragnostics Ltd.

Previous Previous Previous Next Next Next

“Our company name Ariceum, is an anagram of Nobel Laureate physicist and chemist Marie Curie, whose pioneering work is still the foundation of modern radiotherapeutics.”

Vision

Create a better future for cancer patients

Mission

Innovate by caring about patients

Become the go-to-company for more specific and more effective radiopharmaceuticals

Unleashing the power of radiopharmaceuticals

Develop better targeted drugs to eradicate cancer more efficiently
with less side-effects

Our Core Values

Innovation

Scientific rigor

Understanding needs of Patients, Doctors and Caregivers

© Ariceum Therapeutics

Website by FisherPaul

  • Imprint
  • Privacy Policy

Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.